An ever-growing role for a tiny lipid
Critical signaling functions have been attributed to phosphatidic acid, or PA, the smallest building block in phospholipid biosynthesis. With a small head group and a net negative charge ranging from -1 to -2 depending on pH, PA can modulate local membrane geometry and recruit a large set of specific proteins to confined membrane subdomains; a recent review by Emeline Tanguy and colleagues summarizes both of these essential actions for PA’s signaling function. PA is versatile and challenging because it can be produced and metabolized by a large set of enzymes.
Although PA is present at low levels in most cell types, it appears to be critical for neuronal and glial cell function. Several neurological diseases maybe attributed, at least in part, to altered PA synthesis and/or catabolism. For example, Ricardos Tabet and colleagues proposed in 2016 that an alteration of the PA/diacylglycerol balance could be a main cause of fragile X syndrome, a genetic cause of intellectual disability. They showed that diacylglycerol kinase-kappa, or DGK-kappa, mRNA was the main target of fragile X mental retardation protein and that reduced DGK-kappa expression impaired PA synthesis in neurons from mice bred not to express FMR1, a protein that male fragile X patients lack. Silencing DGK-kappa in pyramidal neurons from the CA1 region of the hippocampus largely reproduced fragile X symptoms. This PA/DAG imbalance is thus likely to affect DAG and PA downstream signaling required for both maturation of dendritic spines and establishment of correct synaptic plasticity.
Maria Zeniou–Meyer and colleagues in 2008 proposed that the loss of expression of the kinase RSK2, which leads to Coffin–Lowry syndrome (a rare syndromic form of mental retardation), reduced PA synthesis and distorted neurosecretion. Increased PA synthesis has been reported in gliobastoma, the most frequent and aggressive brain cancer. A link between brain PA levels and Alzheimer’s disease also is starting to emerge, but the exact effects of PA imbalance in neurodegeneration and cognitive deficits has not been identified. Finally, reduced PA synthesis may contribute to fetal alcohol spectrum disorders, as ethanol leads to phospholipase D-mediated phosphatidylethanol production at the expense of PA.
Many cellular pleiotropic functions of PA rely on its ability to regulate actin cytoskeleton dynamics and to modulate membrane-involved functions. The former occurs mainly through PA’s ability to modulate the activity of small GTPases, including Rho and Arf members. The latter probably results both from the original cone shape structure of PA favoring negative membrane curvature and from PA’s net negative charge allowing local recruitment of specific proteins. One remaining challenge is to define precisely sites of PA synthesis within the brain and at the subcellular level in neurons. Recent improvements in lipidomics allow for sensitive quantification of dozens of PA species made with different fatty acids. According to a study by Nawal Kassas and colleagues, the development of novel genetically encoded PA sensors also will be crucial in localizing and potentially quantifying changes in PA and perhaps different PA species.
Despite PA’s low abundance, its relative simplicity, and the complexity of its metabolic and signaling pathways, improved understanding of its multiple functions in brain development and function is now within reach.
Join the ASBMB Today mailing list
Sign up to get updates on articles, interviews and events.
Scientists at eight institutions in the U.S. and Europe have used a protein interaction map to identify 69 drugs that might work against SARS-CoV-2, the virus that causes COVID-19.
The pipetting robots are already in place, but that doesn’t make it easy. Here's how academic laboratories are quickly pivoting to provide testing for the coronavirus.